VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration
- 333 Downloads
To investigate the association between the vascular endothelial growth factor (VEGF) gene and response to either intravitreal bevacizumab (IVB) or photodynamic therapy with intravitreal triamcinolone acetonide and IVB (triple therapy) for neovascular age-related macular degeneration (AMD).
The study consisted of 94 patients with neovascular AMD who underwent IVB and 79 patients with neovascular AMD who underwent triple therapy. Genotypes were determined for four selected tagging single-nucleotide polymorphism (SNP)s of the VEGF gene.
Of the four SNPs studied, one SNP (rs699946) was associated significantly with visual acuity (VA) changes 12 months after treatment—irrespective of whether they received IVB alone (P = 0.044) or triple therapy 0.010). Baseline VA was not significantly different among the three genotypes of rs699946 in either treatment group. There were no significant differences in the number of treatments, incidence of recurrence, or the period until the recurrence according to VEGF rs699946 genetic variant.
The VEGF gene SNP rs699946 was associated with response to IVB alone and to triple therapy in this study. The G allele in SNP rs699946 can thus be applied as a marker for better visual prognosis in patients with neovascular AMD who receive either IVB or triple therapy.
KeywordsBevacizumab Photodynamic therapy Vascular endothelial growth factor
The authors wish to thank Drs Norimoto Gotoh, Hisako Hayashi, Sotaro Ooto, and Hiroshi Tamura for their valuable contributions to this study. This study was supported in part by Grants-in-aid for scientific research (nos. 21249084 and 200791294) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan.
- 2.Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329–45.Google Scholar
- 9.Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–68.PubMedGoogle Scholar
- 25.Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology. 2009.Google Scholar
- 40.Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2009.Google Scholar
- 45.Pabst S, Karpushova A, Diaz-Lacava A, Herms S, Walier M, Zimmer S et al. VEGF gene haplotypes are associated with sarcoidosis. Chest. 2009.Google Scholar